{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:12:49Z","timestamp":1788952369704,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00198-025-07601-2","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T10:29:39Z","timestamp":1752316179000},"page":"1661-1669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Trends in serum phosphate, calcium, and parathyroid hormone levels according to renal function following denosumab"],"prefix":"10.1007","volume":"36","author":[{"given":"Jin Hyeog","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Jae","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0917-2872","authenticated-orcid":false,"given":"Jung Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"issue":"5","key":"7601_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40620-017-0404-z","volume":"30","author":"J Bover","year":"2017","unstructured":"Bover J, Bailone L, L\u00f3pez-B\u00e1ez V, Benito S, Ciceri P, Galassi A et al (2017) Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol 30(5):677\u2013687. https:\/\/doi.org\/10.1007\/s40620-017-0404-z","journal-title":"J Nephrol"},{"issue":"1","key":"7601_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","volume":"23","author":"A Denic","year":"2016","unstructured":"Denic A, Glassock RJ, Rule AD (2016) Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis 23(1):19\u201328. https:\/\/doi.org\/10.1053\/j.ackd.2015.08.004","journal-title":"Adv Chronic Kidney Dis"},{"issue":"7","key":"7601_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","volume":"14","author":"S Klawansky","year":"2003","unstructured":"Klawansky S, Komaroff E, Cavanaugh PF, Mitchell DY, Gordon MJ, Connelly JE et al (2003) Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14(7):570\u2013576. https:\/\/doi.org\/10.1007\/s00198-003-1435-y","journal-title":"Osteoporos Int"},{"issue":"6","key":"7601_CR4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2215\/CJN.11031017","volume":"13","author":"P Khairallah","year":"2018","unstructured":"Khairallah P, Nickolas TL (2018) Management of osteoporosis in CKD. Clin J Am Soc Nephrol 13(6):962\u2013969. https:\/\/doi.org\/10.2215\/CJN.11031017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"7601_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71(1):31\u201338. https:\/\/doi.org\/10.1038\/sj.ki.5002009","journal-title":"Kidney Int"},{"key":"7601_CR6","doi-asserted-by":"publisher","unstructured":"KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017 Jul;7(1):1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001. Epub 2017 Jun 21. Erratum in: Kidney Int Suppl (2011). 2017 Dec;7(3):e1. https:\/\/doi.org\/10.1016\/j.kisu.2017.10.001","DOI":"10.1016\/j.kisu.2017.04.001"},{"issue":"1","key":"7601_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00198-017-4228-4","volume":"29","author":"HH Malluche","year":"2018","unstructured":"Malluche HH, Monier-Faugere MC, Blomquist G, Davenport DL (2018) Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors. Osteoporos Int 29(1):125\u2013134. https:\/\/doi.org\/10.1007\/s00198-017-4228-4","journal-title":"Osteoporos Int"},{"issue":"4","key":"7601_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.ajkd.2020.12.024","volume":"78","author":"M Pazianas","year":"2021","unstructured":"Pazianas M, Miller PD (2021) Osteoporosis and chronic kidney disease-mineral and bone disorder (CKD-MBD): Back to Basics. Am J Kidney Dis 78(4):582\u2013589. https:\/\/doi.org\/10.1053\/j.ajkd.2020.12.024","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"7601_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003954","volume":"19","author":"BR Fletcher","year":"2022","unstructured":"Fletcher BR, Damery S, Aiyegbusi OL, Anderson N, Calvert M, Cockwell P et al (2022) Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis. PLoS Med 19(4):e1003954. https:\/\/doi.org\/10.1371\/journal.pmed.1003954","journal-title":"PLoS Med"},{"issue":"1","key":"7601_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L et al (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int 92(1):26\u201336. https:\/\/doi.org\/10.1016\/j.kint.2017.04.006","journal-title":"Kidney Int"},{"key":"7601_CR11","doi-asserted-by":"crossref","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 66(12):1139.","DOI":"10.1111\/ijcp.12022"},{"issue":"8","key":"7601_CR12","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26(8):1829\u20131835. https:\/\/doi.org\/10.1002\/jbmr.403","journal-title":"J Bone Miner Res"},{"issue":"2","key":"7601_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","volume":"106","author":"A Broadwell","year":"2021","unstructured":"Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S et al (2021) Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106(2):397\u2013409. https:\/\/doi.org\/10.1210\/clinem\/dgaa851","journal-title":"J Clin Endocrinol Metab"},{"key":"7601_CR14","doi-asserted-by":"publisher","unstructured":"Jalleh R, Basu G, Le Leu R, Jesudason S (2018) Denosumab-induced severe hypocalcaemia in chronic kidney disease. Case Rep Nephrol. 2018():7384763. https:\/\/doi.org\/10.1155\/2018\/7384763","DOI":"10.1155\/2018\/7384763"},{"issue":"8","key":"7601_CR15","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00198-018-4533-6","volume":"29","author":"C Thongprayoon","year":"2018","unstructured":"Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B et al (2018) Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int 29(8):1737\u20131745. https:\/\/doi.org\/10.1007\/s00198-018-4533-6","journal-title":"Osteoporos Int"},{"key":"7601_CR16","doi-asserted-by":"crossref","unstructured":"World Medical Association (2013) Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053","DOI":"10.1001\/jama.2013.281053"},{"issue":"9","key":"7601_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"issue":"5","key":"7601_CR18","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","volume":"63","author":"LA Inker","year":"2014","unstructured":"Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA et al (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63(5):713\u2013735. https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.416","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"7601_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1159\/000169030","volume":"16","author":"RN Foley","year":"1996","unstructured":"Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O\u2019Dea R et al (1996) Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 16(5):386\u2013393. https:\/\/doi.org\/10.1159\/000169030","journal-title":"Am J Nephrol"},{"issue":"1","key":"7601_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12890-021-01784-0","volume":"21","author":"M Murthi","year":"2021","unstructured":"Murthi M, Shaka H, El-Amir Z, Velagapudi S, Jamil A, Wani F et al (2021) Association of hypocalcemia with in-hospital mortality and complications in patients with acute pulmonary embolism: results from the 2017 Nationwide Inpatient Sample. BMC Pulm Med 21(1):410. https:\/\/doi.org\/10.1186\/s12890-021-01784-0","journal-title":"BMC Pulm Med"},{"issue":"8","key":"7601_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cardfail.2015.04.015","volume":"21","author":"S Miura","year":"2015","unstructured":"Miura S, Yoshihisa A, Takiguchi M, Shimizu T, Nakamura Y, Yamauchi H et al (2015) Association of hypocalcemia with mortality in hospitalized patients with heart failure and chronic kidney disease. J Card Fail 21(8):621\u2013627. https:\/\/doi.org\/10.1016\/j.cardfail.2015.04.015","journal-title":"J Card Fail"},{"issue":"1\u20133","key":"7601_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000492918","volume":"47","author":"A Carlo","year":"2019","unstructured":"Carlo A, Anna R, Francesca Z, Simone V, Mario C, Piergiorgio M (2019) The importance of adherence in the treatment of secondary hyperparathyroidism. Blood Purif 47(1\u20133):37\u201344. https:\/\/doi.org\/10.1159\/000492918","journal-title":"Blood Purif"},{"issue":"19","key":"7601_CR23","doi-asserted-by":"publisher","first-page":"6306","DOI":"10.3390\/jcm12196306","volume":"12","author":"M Fusaro","year":"2023","unstructured":"Fusaro M, Pereira L, Bover J (2023Sep 30) Current and emerging markers and tools used in the diagnosis and management of chronic kidney disease-mineral and bone disorder in non-dialysis adult patients. J Clin Med 12(19):6306. https:\/\/doi.org\/10.3390\/jcm12196306","journal-title":"J Clin Med"},{"key":"7601_CR24","doi-asserted-by":"publisher","unstructured":"Bover J, Mass\u00f3 E, Gifre L, Alfieri C, Soler-MJ, Fusaro M et al. Vitamin D and chronic kidney disease association with mineral and bone disorder: an appraisal of tangled guidelines. Nutrients. 2023 Mar 24;15(7):1576. https:\/\/doi.org\/10.3390\/nu15071576","DOI":"10.3390\/nu15071576"},{"issue":"15","key":"7601_CR25","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.3390\/nu14153009","volume":"14","author":"V Brandenburg","year":"2022","unstructured":"Brandenburg V, Ketteler M (2022Jul 22) Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future. Nutrients 14(15):3009. https:\/\/doi.org\/10.3390\/nu14153009","journal-title":"Nutrients"},{"issue":"2","key":"7601_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/er.2007-0014","volume":"29","author":"AE Kearns","year":"2008","unstructured":"Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29(2):155\u2013192. https:\/\/doi.org\/10.1210\/er.2007-0014","journal-title":"Endocr Rev"},{"issue":"4","key":"7601_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cen.12188","volume":"79","author":"P Makras","year":"2013","unstructured":"Makras P, Polyzos SA, Papatheodorou A, Kokkoris P, Chatzifotiadis D, Anastasilakis AD (2013) Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf) 79(4):499\u2013503. https:\/\/doi.org\/10.1111\/cen.12188","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"7601_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/jcpt.12753","volume":"44","author":"T Imatoh","year":"2019","unstructured":"Imatoh T, Sai K, Takeyama M, Hori K, Karayama M, Furuhashi K et al (2019) Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia. J Clin Pharm Ther 44(1):62\u201368. https:\/\/doi.org\/10.1111\/jcpt.12753","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"7601_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000499824","volume":"9","author":"J Strickling","year":"2019","unstructured":"Strickling J, Wilkowski MJ (2019) Severe, Symptomatic hypocalcemia due to denosumab administration: treatment and clinical course. Case Rep Nephrol Dial 9(1):33\u201341. https:\/\/doi.org\/10.1159\/000499824","journal-title":"Case Rep Nephrol Dial"},{"issue":"4","key":"7601_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s00774-022-01331-9","volume":"40","author":"A Horikawa","year":"2022","unstructured":"Horikawa A, Hongo M, Kasukawa Y, Shimada Y, Kodama H, Sano A et al (2022) The relationship between chronic kidney disease and denosumab-induced hypocalcemia in high-age osteoporotic patients. J Bone Miner Metab 40(4):670\u2013676. https:\/\/doi.org\/10.1007\/s00774-022-01331-9","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"7601_CR31","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/ndt\/gfaa359","volume":"36","author":"R Hiramatsu","year":"2021","unstructured":"Hiramatsu R, Ubara Y, Sawa N, Sakai A (2021) Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study. Nephrol Dial Transplant 36(10):1900\u20131907. https:\/\/doi.org\/10.1093\/ndt\/gfaa359","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"7601_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000380960","volume":"41","author":"V Dave","year":"2015","unstructured":"Dave V, Chiang CY, Booth J, Mount PF (2015) Hypocalcemia post denosumab in patients with chronic kidney disease stage 4\u20135. Am J Nephrol 41(2):129\u2013137. https:\/\/doi.org\/10.1159\/000380960","journal-title":"Am J Nephrol"},{"issue":"1","key":"7601_CR33","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1038\/s41598-020-59143-8","volume":"10","author":"K Kunizawa","year":"2020","unstructured":"Kunizawa K, Hiramatsu R, Hoshino J, Mizuno H, Ozawa Y, Sekine A et al (2020) Denosumab for dialysis patients with osteoporosis: a cohort study. Sci Rep 10(1):2496. https:\/\/doi.org\/10.1038\/s41598-020-59143-8","journal-title":"Sci Rep"},{"issue":"7","key":"7601_CR34","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1210\/jc.2014-1154","volume":"99","author":"CL Chen","year":"2014","unstructured":"Chen CL, Chen NC, Hsu CY, Chou KJ, Lee PT, Fang HC et al (2014) An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 99(7):2426\u20132432. https:\/\/doi.org\/10.1210\/jc.2014-1154","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"7601_CR35","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/jog.13913","volume":"45","author":"S Saito","year":"2019","unstructured":"Saito S, Sugo Y, Tsuburai T, Kurasawa K, Nakamura T, Yoshikata H et al (2019) Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. J Obstet Gynaecol Res 45(4):908\u2013914. https:\/\/doi.org\/10.1111\/jog.13913","journal-title":"J Obstet Gynaecol Res"},{"issue":"7","key":"7601_CR36","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1210\/jc.2015-1259","volume":"100","author":"CL Chen","year":"2015","unstructured":"Chen CL, Chen NC, Liang HL, Hsu CY, Chou KJ, Fang HC et al (2015) Effects of denosumab and calcitriol on severe secondary hyperparathyroidism in dialysis patients with low bone mass. J Clin Endocrinol Metab 100(7):2784\u20132792. https:\/\/doi.org\/10.1210\/jc.2015-1259","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"7601_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bcp.12355","volume":"78","author":"W Sohn","year":"2014","unstructured":"Sohn W, Simiens MA, Jaeger K, Hutton S, Jang G (2014) The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review. Br J Clin Pharmacol 78(3):477\u2013487. https:\/\/doi.org\/10.1111\/bcp.12355","journal-title":"Br J Clin Pharmacol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07601-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07601-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07601-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:04:46Z","timestamp":1758747886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07601-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7601"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07601-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of Yongin Severance Hospital Clinical Trial Center (IRB no. 9\u20132022-0061) approved the use of this retrospective observational study. Since data were evaluated retrospectively, pseudonymously, and were solely obtained for treatment purposes, a requirement of informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Participants provided informed consent for participation in this anonymous survey prior to survey completion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Participants provided informed consent for the publication of anonymized data prior to survey completion. All authors and responsible authorities at the approving institution have consented to the submission of this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}